CLINICAL TRIALS PROFILE FOR VALOPICITABINE

Clinical Trials for Valopicitabine

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00118768 ↗	A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C	Completed	Merck Sharp & Dohme Corp.	Phase 2	This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety and effectiveness of valopicitabine alone and together with Pegylated Interferon (a drug approved by the Food and Drug Administration for the treatment of Hepatitis C infection).
NCT00120835 ↗	Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C	Completed	Merck Sharp & Dohme Corp.	Phase 1/Phase 2	This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug Administration for the treatment of hepatitis C infection. This study is also evaluating the ability of valopicitabine to decrease the amount of hepatitis C virus in the body. The results for patients taking valopicitabine alone will be compared with the results for patients taking valopicitabine together with pegylated interferon.
NCT00120861 ↗	Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy	Completed	Merck Sharp & Dohme Corp.	Phase 2	This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure patients. These results will be compared against the results of treatment with pegylated interferon plus ribavirin, the current standard therapy for treatment of hepatitis C viral infection.
NCT00395421 ↗	Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin	Completed	Novartis Pharmaceuticals	Phase 2	This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.
NCT00395421 ↗	Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin	Completed	Merck Sharp & Dohme Corp.	Phase 2	This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.

Clinical Trial Conditions for Valopicitabine

Condition Name

Condition Name
Intervention	Trials
Chronic Hepatitis C	4

Condition MeSH

Condition MeSH
Intervention	Trials
Hepatitis C	4
Hepatitis	4
Hepatitis, Chronic	4
Hepatitis C, Chronic	4

Clinical Trial Locations for Valopicitabine

Trials by Country

Trials by Country
Location	Trials
United States	29
Puerto Rico	1

Trials by US State

Trials by US State
Location	Trials
Texas	3
Florida	3
New York	2
Michigan	2
Massachusetts	2

Clinical Trial Progress for Valopicitabine

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	3
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for Valopicitabine

Sponsor Name

Sponsor Name
Sponsor	Trials
Merck Sharp & Dohme Corp.	4
Novartis Pharmaceuticals	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	5